Brief: AB Science Granted Authorization To Initiate Study Of AB8939
18/10/2021 17:30
Oct 18 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH
AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT
OF ACUTE MYELOID LEUKEMIA (AML)
* SECOND AUTHORIZATION FOR PHASE I/II TRIAL AB18001 PERMITS
PATIENT RECRUITMENT FROM STUDY SITES IN FRANCE AND CANADA
Source text for Eikon: ID:nGNE3k08xy
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease